News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Nivedita Rangarajan

Articles by Nivedita Rangarajan

48 Prevalence of “HER2 Ultra-Low” Among Advanced Breast Cancer Patients With Historical IHC0 Status

ByAnushree Iyengar,Sandhya Mehta,Hannah Barman,Nivedita Rangarajan,Sue-Ann Woo,Simone T. Sredni,Rosemarie Di Donato,Safak Simsek,Erinn P. Downs,Aziza Nassar,Darren M. Wilson,Katherine Krieser,Elise Bieri Patzke,Natalie Kyek,Jason Hipp,Tyler Wagner, PhD

May 25th 2025

Latest Updated Articles

Trending on CancerNetwork

FDA Approves Gedatolisib for HR+, HER2– PIK3CA Wild-Type Advanced Breast Cancer

Managing Gedatolisib IV Delivery and Toxicity Profiles in Breast Cancer

Gedatolisib Approval in HR+/HER2- Breast Cancer May Be “Practice Changing”

Pembrolizumab Monotherapy Improves PFS in Frontline dMMR Endometrial Cancer

FDA Accepts NDA for Mezigdomide Combo in R/R Multiple Myeloma